Successful bone implant boosts Bonus BioGroup

Prof. Shai Meretzki  photo: Avshalom Shoshani
Prof. Shai Meretzki photo: Avshalom Shoshani

The implant was created using technology developed by Bonus BioGroup cofounder, president, and CEO Prof. Shai Meretzki.

Trading in the shares of stem cell company Bonus BioGroup Ltd. (TASE: BONS ) was halted, after a first patient successfully underwent a bone implant developed by the company. Halting trading in a share because of the first patients in a clinical trial is an exceptional measure for medical companies, including those that make products just as innovative as those of Bonus BioGroup. Most companies announce such matters in an ordinary announcement to the stock exchange, or do not make any announcement at all. Following the announcement and unusual media coverage accompanying the event, Bonus BioGroup's shares rose 15% when trading resumed, pushing its market cap up to NIS 400 million.

Bonus BioGroup announced in August its intention of treating the first three patients in its clinical trial, and the announcement concerns the first patient treated with its product. The implant took place yesterday, so it is still unknown whether the implant was successfully absorbed and what the clinical results will be, meaning the effect on the patient's ability to walk.

The implant was created using innovative technology developed by Bonus BioGroup cofounder, president, and CEO Prof. Shai Meretzki (the other co-founder is chairperson Yossi Rauch). Stem cells from the patient's adipose tissue were harvested from the patient's body and sorted in a bone cells laboratory. They were grown on a scaffold designed in a form adjusted to the patient's bone. Bonus BioGroup says that the patient was in an accident, and his bone was set mechanically, but even after two setting operations, he still lacked bone, which restricted his activity, with a constant risk of a fracture in the remaining bone.

A long road to market

Bonus BioGroup still has a long way to go before its product reaches the market and is successful. The company has to show that the implants not only grow well, but are also absorbed well without rejection, and are integrated with the existing bone in a way that improves the patient's situation. It must also compare these results to those of a control group treated with the standard procedure. At the same time, it should be noted that the regulatory route for stem cell products originating in the patient's own cells is shorter when the cells come from an external source.

At the same time, it should be noted that the regulatory route for stem cell products originating in the patient's own cells is shorter when the cells come from an external source. It should also be noted that the potential market is very large. Bonus still has no revenue, and had NIS 2 million cash as of the end of the third quarter of 2017. The company's burn rate in the first nine months of the year was NIS 9.6 million, which was used for its current activity. Bonus BioGroup has previously said that it is planning a Nasdaq offering, but this plan has yet to materialize.

Published by Globes [online], Israel Business News - www.globes-online.com - on December 20, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

Prof. Shai Meretzki  photo: Avshalom Shoshani
Prof. Shai Meretzki photo: Avshalom Shoshani
Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018